Skip to main content

Hypoxic Tumour Models for Photoactivatable Ruthenium-based Chemotherapy

Obiettivo

In this Proof-of-Concept project I will show the commercial potential of ruthenium-based photoactivated chemotherapy (PACT) compounds developed in my ERC Starting Grant by demonstrating their efficacy on hypoxic cancer models. Photoactivated chemotherapy is a new class of phototherapy to treat cancer. In principle, PACT looks similar to photodynamic therapy (PDT): light irradiation of the tumour in vivo leads to local activation of the anticancer prodrug, thereby limiting the toxicity of the treatment to the diseased tissue, and thus lowering side effects for the patient. However, the mechanisms of PACT and PDT are very different: in PDT the light-absorbing prodrug requires molecular oxygen to kill the cancer cells, whereas in PACT oxygen is not involved in prodrug activation. As a consequence, PACT agents should be able to treat hypoxic tumours, which are characterized by low oxygen concentrations and high resistance to PDT and other existing therapies. In this project the efficacy of a selection of Ru-based PACT compounds will be tested in hypoxic cancer models and compared to their efficacy in normoxic conditions. In parallel I will develop, in collaboration with my network of collaborators from the clinics, business analysts, and patent attorney, a plan for (pre) clinical development of PACT compounds.

Invito a presentare proposte

ERC-2017-PoC
Vedi altri progetti per questo bando

Meccanismo di finanziamento

ERC-POC - Proof of Concept Grant

Istituzione ospitante

UNIVERSITEIT LEIDEN
Indirizzo
Rapenburg 70
2311 EZ Leiden
Paesi Bassi
Tipo di attività
Higher or Secondary Education Establishments
Contributo UE
€ 150 000

Beneficiari (1)

UNIVERSITEIT LEIDEN
Paesi Bassi
Contributo UE
€ 150 000
Indirizzo
Rapenburg 70
2311 EZ Leiden
Tipo di attività
Higher or Secondary Education Establishments